Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | UNK | Unknown | — |
The patient took one dose of expired product Vivotif; Case reference number US-BN-2025-001761 is a spontaneous case report initially received from other health professional via Bavarian Nordic (reference number: CASE-000585) on 04-Nov-2025 and concerns female patient of unspecified age. The patient's relevant medical history and concomitant medications were not provided. On unspecified date in May-2025, patient picked up Vivotif. On an unspecified date, the patient took first dose of Vivotif vaccine and noticed it was expired in Aug-2025 (batch number: unknown) at unknown dose, route or site of administration for unknown indication (Explicitly coded as 'expired product administered'). At the time of initial report, it was unknown if the patient experienced any adverse event due to Vivotif. No further information provided.; Sender's Comments: This case concerns a female patient of unspecified age, had received the first dose of Vivotif vaccine for unknown indication, which was expired, which is considered as expired vaccine used. At the time of initial report, it was unknown if the patient experienced any adverse event due to Vivotif. Expired vaccine used is considered as listed as per company convention. The patient's medical history and concomitant medication details were not provided. Event expired vaccine used is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None.